Physician profile
Amirtha Ajit
NPI 1881688422
$890.47
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $561 · 2020: $82.87 · 2021: $43.13 · 2023: $53.49 · 2024: $150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $207.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $170.28 | 2019-2020 | |
| Pfizer INC. | $77.01 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.79 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $65.73 | 2019-2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $60.90 | 2023-2024 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $43.80 | 2019-2020 | |
| Medtronic Vascular, INC. | $37.33 | 2019 | |
| Abbvie INC. | $31.62 | 2021-2023 | Ubrelvy |
| Nevro Corp. | $29.33 | 2021 | |
| Allergan, INC. | $24.83 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.58 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.44 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.39 | 2023 | Quviviq |
| Lilly USA, LLC | $15.52 | 2024 | Jardiance, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amirtha Ajit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.